Home » Newsletters » BioWorld Science

BioWorld Science

April 22, 2014

View Archived Issues

FGFR inhibitor active against cells harboring genetic mutations

Genetic loci associated with ovarian cancer prognosis

Novel miRNA biomarkers for predicting response to cardiac procedures

Researchers present further clinical data for Liproca depot

Cyclophilin inhibitor NVP-018 inhibits HBV preclinically

Scientists at Vitae Pharmaceuticals design new BACE1 inhibitors

Neuralstem gains permission to conduct chronic spinal cord injury trial

Preclinical in vivo transplantation of human stem-cell derived hepatocytes for liver cell therapy

Islet Sciences reports phase II data for remogliflozin etabonate

Kyowa Hakko Kirin and Amgen terminate agreement for mogamulizumab

Researchers in the U.S. disclose new tyrosine-protein kinase inhibitors

Adamed presents a novel bioconjugate for tumor-targeted drug delivery

Merck & Co. designs novel SYK inhibitors

French researchers patent new agents for tuberculosis and leprosy

French group synthesizes novel agents for cancer

Kissei launches Savene in Japan

NeuroVive Pharmaceutical reports on breakthrough in cellular energy regulation

Torii Pharmaceutical set to launch Riona in Japan for the treatment of hyperphosphatemia

Cyclenium and Southern Research Institute form drug discovery collaboration

Lilly's VEGF-inhibiting monoclonal antibody approved for gastric cancer

Volasertib granted orphan drug designation in the E.U. and U.S.

Ragwitek sublingual immunotherapy approved by FDA for hay fever

GSK-2586184 meets primary endpoint in psoriasis study

Akorn completes acquisition of Hi-Tech Pharmacal

Can-Fite and Smart Assays to develop A3AR biomarker test kit

FDA approves ofatumumab in untreated chronic lymphocytic leukemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...